Prevention of adverse effects of BCG immunotherapy in bladder cancer.
Naoe
Michio
M
Ogawa
Yosio
Y
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D015242:Ofloxacin / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D001500:BCG Vaccine; D019384:Nucleic Acid Synthesis Inhibitors; D015242:Ofloxacin